The myth of the biotech revolution: An assessment of technological, clinical and organisational change

Research Policy

Volumn 36, Issue 4, 2007, Pages 566-589

  Hopkins, Michael M ^a   Martin, Paul A ^b   Nightingale, Paul ^a   Kraft, Alison ^b   Mahdi, Surya ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Biotechnology; Innovation; Policy; Revolution

Indexed keywords

HEALTH CARE; HEURISTIC METHODS; INNOVATION; SOCIAL ASPECTS; STRATEGIC PLANNING; TECHNOLOGY TRANSFER;

EMPIRICAL EVIDENCE; REVOLUTION; TECHNOLOGICAL CHANGE;

BIOTECHNOLOGY;

EID: 34247555321     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2007.02.013     Document Type: Article

References (135)

1. Angell M. The Truth about Drug Companies (2004), Random House, New York
2. Ariens E.J. Molecular Pharmacology, Medicinal Chemistry Series (1964), The Academic Press p. xvi
3. Arnst, C., 2005. Biotech, finally. Business Week, 13 June, pp. 41-46.
4. Arundel, A., Mintzes, B., 2004. The impact of biotechnology on health. Merit-Innogen Working Paper. University of Edinburgh-Open University, Edinburgh and Bucks.
5. AstraZeneca, 2001. Annual Report and Form 20-F. Available from http://www2.astrazeneca.com/annualrep2001/default.asp.
6. Bell J. The new genetics in clinical practice. British Medical Journal 316 (1998) 618-620
7. Bell J.I. The double helix in clinical practice. Nature 421 (2003) 414-416
8. Bergman, G., 2004. Today's biotech breakthroughs are saving the lives of patients, Letter to the, The Financial Times, 18 November, p. 20.
9. Bijker W.E. Of Bicycles, Bakelite and Bulbs: Towards a Theory of Socio-technical Change (1995), MIT Press, Cambridge, MA
10. Bioscience, Innovation and Growth Team (BIGT). Bioscience 2015 (2003), DTI, London
11. Bognor W.C. Drugs to Market (1996), Pergamon Press, London
12. Bolten B.M., and DeGregorio T. Trends in development cycles. Nature Reviews Drug Discovery 1 (2002) 335-336
13. Booth B., and Zemmel R. Prospects for productivity. Nature Reviews Drug Discovery 2 (2004) 451-456
14. Bowe, G., 2006. Big biotech fears becoming a victim of its own success. Financial Times, 20 July (online).
15. Brekke O.H., and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the 21st century. Nature Reviews Drug Discovery 2 (2003) 52-62
16. Bud R. The Uses of Life: A History of Biotechnology (1993), Cambridge University Press, Cambridge
17. Callon M. Some elements of a sociology of translation: domestication of the scallops and the fishermen of St. Brieuc Bay. In: Law J. (Ed). Power Action and Belief: A New Sociology of Knowledge? (1986), Routledge and Kegan Paul, London 196-223
18. Callon M. The sociology of an actor network: the case of the electric vehicle. In: Callon M., Law J., and Rip A. (Eds). Mapping the Dynamics of Science and Technology: Sociology of Science in the Real World (1986), Macmillan, Basingstoke 19-34
19. Campbell N. The impact of whole, assembled genomes on the drug development process. European Biopharma Review March (2001) 52-58
20. Cantor C. The challenges to technology and informatics. In: Kevles D., and Hood L. (Eds). The Code of Codes (1992), Harvard University Press, Cambridge, MA 98-111
21. Chandler A.D. Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries (Harvard Studies in Business History) (2005), Harvard University Press, Cambridge, MA
22. Chu, W.L., 2006. Has new technology hampered R&D productivity? Drugresearcher.com, 30/03/06, http://www.drugresearcher.com/news/ng.asp?id=66772.
23. Collins F.S., Patrinos A., Jordan E., Chakravarti A., Gesteland R., and Walters L. New goals for the human genome project. Science 282 (1998) 682-689
24. Cooper R.S., and Psaty B.M. Genomics and medicine: distraction, incremental progress, or the dawn of a new age?. Ann Intern. Med. 138 7 (2003) 576-580
25. Crafts N. Steam as a general purpose technology: a growth accounting perspective. The Economic Journal 114 (2004) 338
26. David P.A. The dynamo and the computer: an historical perspective on the modern productivity paradox. The American Economic Review 80 2 (1990) 355-361
27. De Hoffmann E., and Stroobant V. Mass Spectrometry (2001), John Wiley and Sons, New York
28. Department of Health. The Genetics of Common Diseases (1995), HMSO, London
29. Department of Health. Our Inheritance, Our Future: Realising the Potential of Genetics in the NHS (2003), HMSO, London
30. Devine Jr. W.D. From shafts to wires: historical perspectives on electrification. The Journal of Economic History 43 (1983) 347-372
31. Dibner M. Biotechnology's contribution to pharmaceuticals. Trends in Biomedical Research (1993 6 Sept) 553-558
32. Dickson M., and Gagnon J.P. Key factors in the rising cost of new drug discovery and development. Nature Reviews Drug Discovery 3 (2004) 417-429
33. DiMasi J.A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69 (2001) 297-307
34. Dohse D. Technology policy and the regions - the case of the BioRegio contest. Research Policy 20 9 (2000) 1111-1133
35. Drews J. Genomic sciences and the medicine of tomorrow. Nature Biotechnology 14 (1996) 1516-1518
36. Drews J., and Ryser S. The role of innovation in drug development. Nature Biotechnology 15 (1997) 1318-1319
37. DTI (Department of Trade and Industry). Biotechnology Clusters (1999), HMSO, London
38. DTI (Department of Trade and Industry). Science and Innovation Strategy (2001), DTI, London
39. Edgington S.M. Super-family structure and biotech drug development. Biotechnology 10 (1992) 1529-1534
40. Enriquez J., and Goldberg R.A. Transforming life, transforming business: the life-science revolution. Harvard Business Review 78 2 (2000) 94-104
41. Ernst and Young. Refocus: The European Perspective Global Biotechnology Report (2004), Ernst and Young, London
42. European Commission, 2002. Life Sciences and Biotechnology - A Strategy for Europe Commission, 27. European Commission, Brussels.
43. FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (2004), US Department of Health and Human Services, Food and Drug Administration, Bethesda, MA
44. Freeman C. The Economics of Industrial Innovation. second ed. (1982), Frances Pinter, London
45. Freeman C., and Louca F. As Time Goes By: From the Industrial Revolution to the Information Revolution (2002), Oxford University Press, Oxford
46. Friedrich G.A. Moving beyond the genome projects. Nature Biotechnology 14 (1996) 1234-1237
47. Galambos L., and Sewell J. Networks of Innovation: Vaccine Development at Merck, Sharp, Dohme and Mulford 1895-1995 (1995), Cambridge University Press, Cambridge
48. Galambos L., and Sturchio J.L. Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation. Business History Review 72 (1998) 250-278
49. Gassmann O., Reepmeyer G., and von Zedtwitz M. Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry (2004), Springer, London
50. Giesecke S. The contrasting roles of government in the development of biotechnology industry in the US and Germany. Research Policy 29 2-3 (2000) 205-223
51. Gilbert W. A vision of the grail. In: Kevles D., and Hood L. (Eds). The Code of Codes (1992), University Press, Cambridge, MA 83-97
52. Glassman R.H., and Sun A.Y. Biotechnology: identifying advances from the hype. Nature Reviews Drug Discovery 3 (2004) 177-183
53. Goodman, J., Walsh, V., 1993. Little and big heuristics: medicine, chemistry and pharmaceutical production on nineteenth-century Europe. In: Paper presented at the SHOT Technological Change Conference, Oxford, September.
54. Guice J. Designing the future: the culture of new trends in science and technology. Research Policy 28 (1999) 81-98
55. Hackett J.L., and Lesko L.J. Microarray data - the US FDA, industry and academia. Nature Biotechnology 21 7 (2003) 742-743
56. Handwerk, B., 2005. Bird-Flu fears spur sales of star anise spice. National Geographic News, at www.nationalgeographic.com/news2005/11/1128_051128_star_anise.html.
57. Happold F.H. Medicine at Risk (1967), Queen Anne Press, London
58. Harris H. The Cells of the Body (1995), Coldspring Harbour Press, New York
59. Hedgecoe A., and Martin P. The drugs don't work: expectations and the shaping of pharmacogenetics. Social Studies of Science 33 3 (2003) 327-364
60. Higgs G. Molecular genetics: the emperor's clothes of drug discovery?. Drug Discovery Today 9 17 (2004) 727-729
61. Homberg E. The emergence of research laboratories in the dyestuffs industry, 1870-1900. British Journal for the History of Science 25 (1992) 91-111
62. Hood L. Biology and medicine in the twenty-first century. In: Kevles D., and Hood L. (Eds). The Code of Codes (1992), Harvard University Press, Cambridge, MA 136-163
63. Hood L., and Perlmutter R.M. The impact of systems approaches on biological problems in drug discovery. Nature Biotechnology 22 (2004) 1215-1217
64. Hopkins A.L., and Groom C.R. The druggable genome. Nature Reviews Drug Discovery 1 (2002) 727-730
65. Hopkins A.L. Are drugs discovered in the clinic or the laboratory?. Drug Discovery Today 3-5 (2004) 173-175
66. Hopkins M.M., Kraft A., Martin P.A., Nightingale P., and Mahdi S. Is the biotechnology revolution a myth?. In: Taylor, and Triggle (Eds). Comprehensive Medicinal Chemistry. second ed. vol. 1 (2006), Elsevier
67. Hopkins M.M., Ibarreta D., Gaisser S., Enzing C.M., Ryan J., Martin P.A., Lewis G., Symone Detmar S.M., van den Akker-van Marle E., Hedgecoe A.M., Nightingale P., Dreiling M., Hartig K.J., Vullings W., and Forde T. Putting pharmacogenetics into practice. Nature Biotechnology 24 April (2006) 403-410
68. Horrobin D.F. Realism in drug discovery - could Cassandra be right?. Nature 19 (2001) 1099-1100
69. Horrobin D.F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality?. Nature Reviews Drug Discovery 2 (2003) 151-154
70. IPTS (Institute for Prospective Technological Studies), 2006. Pharmacogenetics and pharmacogenomics: state-of-the-art and potential socio-economic impacts in the EU. European Commission Joint Research Centre, available at www.JCR.es.
71. Jack, A., 2006. GSK looks to drug alliances. Financial Times, 30 May, www.FT.com.
72. Jolley J. Pharmaceutical manufacturing into the future. The Pharmaceutical Journal 264 7077 (2000) 26
73. Joppi R., Bertele V., and Garattini S. Disappointing biotech. British Medical Journal 331 (2005) 895-897
74. Kaitin K.I., and DiMasi J.A. Measuring the pace of new drug development in the user fee era. Drug Information Journal 34 (2000) 673-680
75. Kenney M. Schumpeterian innovation and entrepreneurs in capitalism: a case study of the US biotechnology industry. Research Policy 15 (1986) 21-31
76. In: Kevles D., and Hood L. (Eds). The Code of Codes: Scientific and Social Issues in the Human Genome Project (1992), Harvard University Press, Cambridge, MA
77. Kneller R. The origins of new drugs. Nature Biotechnology 23 5 (2005) 529-530
78. Knight P. Non-protein engineering: small drug design. Biotechnology 7 (1990) 105-107
79. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews Drug Discovery 3 7 (2004) 711-715
80. Kramer R., and Cohen D. Functional genomics to new drug targets. Nature Reviews Drug Discovery 3 (2004) 965-972
81. Leheny R. The Fruits of Genomics: Drug Pipelines Face Indigestion until the New Biotechnology Ripens (2001), Lehman Brothers and McKinsey & Company, New York
82. Lenaghan J. Brave New NHS? (1998), IPPR, London
83. Lindpaintner K. Pharmacogenetics and the future of medical practice. British Journal of Clinical Pharmacology 54 (2002) 221-230
84. Littlejohn P. Transtuzumab for early breast cancer: revolution or evolution?. Lancet Oncology 7 1 (2006) 22-23
85. Ma P., and Zemmel R. Value of novelty. Nature Reviews Drug Discovery 1 (2002) 571-572
86. Marshall A. Getting the right drug into the right patient. Nature Biotechnology 15 (1997) 1249-1252
87. Martin, P., 1998. From eugenics to therapeutics: science and the social shaping of gene therapy. Unpublished DPhil thesis, SPRU, University of Sussex, Brighton.
88. Martin P.A. Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease. Sociology of Health and Illness 21 5 (1999) 517-538
89. Martin P.A., and Morrison M.M. Realising the Promise of Genomic Medicine (2006), Royal Pharmaceutical Society, London
90. McCarthy A. Pharmacogenetics: implications for drug development, patients and Society. New Genetics and Society 19 2 (2000) 135-144
91. Mitchell P. Next generation mono-clonals less profitable than trailblazers?. Nature Biotechnology 23 8 (2005) 906
92. Nightingale P. Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D. Journal of Industrial and Corporate Change 9 (2000) 315-359
93. Nightingale P. Technological capabilities, invisible infrastructure and the un-social construction of predictability: the overlooked fixed costs of useful research. Research Policy 33 (2004) 1259-1284
94. Nightingale P., and Mahdi S. The evolution of the pharmaceutical industry. In: Mazzucato M., and Dosi G. (Eds). Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech (2006), Cambridge University Press, Cambridge (Chapter 3)
95. Nightingale P., and Martin M. The myth of the biotech revolution. Trends in Biotechnology 22 (2004) 564-569
96. OECD. Biotechnology and medical innovation: socio-economic assessment of the technology, the potential and the products (1997), OECD, Paris
97. OECD. Economic aspects of biotechnologies related to human health. Part II. Biotechnology, medical innovation and the economy: the key relationships (1998), OECD, Paris
98. OECD, 2004a. Compendium of Patent Statistics. OECD, Paris.
99. OECD, 2004b. Committee for Scientific and Technological Policy at Ministerial Level "Science, Technology and Innovation for the 21st Century", Final Communique Meeting, pp. 29-30.
100. Office of Technology Assessment, 1991. Biotechnology in a Global Economy, OTA-BA-494. US Government Printing Office, Washington, DC, October.
101. Orsenigo L. The Emergence of Biotechnology (1989), Pinter Publishers, London
102. Pavitt K. Sectoral patterns of technological change: towards a taxonomy and a theory. Research Policy 13 (1984) 343-374
103. Pavitt K. Technologies, products and organisations in the innovating firm: What Adam Smith tell us that Joseph Schumpeter doesn't. Industrial and Corporate Change 7 3 (1998) 433-452
104. Pavlou A.K., and Reichert J.M. Recombinant protein therapeutics - success rates, market trends and value to 2010. Nature Biotechnology 22 12 (2004) 1513-1519
105. Pisano G.P. The Development Factory: Unlocking the Potential of Process Innovation (1997), Harvard Business School Press, Boston, MA
106. Pisano G.P. Science Business: The Promise, The Reality, and The Future of Biotech (2006), Harvard Business School Press
107. Pollack, A., 2002. Rebellious bodies dim the glow of "Natural Biotech Drugs". New York Times, 30 July.
108. Porter R. The Greatest Benefit to Mankind (1999), Fontana, London
109. Powell W.W., White D.R., Kogut K.W., and Owen-Smith J. Network dynamics and field evolution: the growth of inter-organizational collaborations in the life sciences. American Journal of Sociology 11 4 (2005) 1132-1205
110. Reichert J.M. Trends in development and approval times for new therapeutics in the United States. Nature Reviews Drug Discovery 2 (2003) 695-702
111. Reichert J.M., Rosenweig C.J., Faden L.B., and Dewtiz M.C. Monoclonal antibody successes in the clinic. Nature Biotechnology 23 9 (2005) 1073-1078
112. Robbins-Roth C. From Alchemy to IPO: The Business of Biotechnology (2000), Perseus Publishing, Cambridge, MA
113. Rodengen J.L. The Legend of Pfizer (1999), Write Stuff Syndicate Inc., Lauderdale, FL
114. Rosenberg N. Technological Interdependence in the American Economy. Technology and Culture 20 1 (1979) 25-51
115. Rosenberg N. Exploring the Black Box (1982), Cambridge University Press, Cambridge, UK
116. Roses A.D. Pharmacogenetics and the practice of medicine. Nature 405 (2000) 857-865
117. Rothman H., and Kraft A. Downstream and into deep biology: evolving business models in 'top tier' genomics companies. Journal of Commercial Biotechnology 12 2 (2006) 86-98
118. Royal Society. Personalised Medicines: Hopes and Realities (2005), Royal Society, London
119. Senker J., Enzing C., Joly P., and Reiss T. European exploitation of biotechnology - do government policies help. Nature Biotechnology 18 (2000) 605-609
120. Service R. Surviving blockbuster syndrome. Science 303 (2004) 1796-1799
121. Shriver Z., Raguram S., and Sasisekharan R. Glycomics: a pathway to a class of new and improved therapeutics. Nature Reviews Drug Discovery 3 (2004) 863-873
122. SmithKline Beecham, 1992. Annual Report. London.
123. Sneader W. Drug Discovery: A History (2005), John Wiley and Sons Ltd., Chichester
124. Stein L.D. End of the beginning. Nature 431 (2004) 915-916
125. Sturgeon T.J. Modular production networks: a new American model of industrial organization. Industrial and Corporate Change 11 3 (2002) 451-496
126. Swann J.P. The evolution of the American pharmaceutical industry. Pharmacy in History 37 2 (1995) 76-86
127. Tollman P., Guy P., Altshuler J., Flanagan A., and Steiner M. A revolution in R&D: how genomics and genetic are transforming the biopharmaceutical industry (2001), The Boston Consulting Group, Boston
128. Van Brunt, J., 2002. Genomics drugs march to the clinic, at www.signalsmag.com.
129. Van Brunt, J., 2004. Biomarkers: the pendulum finally swings, at www.signalsmag.com.
130. von Tunzelmann G.N. Technological and organizational change in industry during the early industrial revolution. In: O'Brien P.K., and Quinault R. (Eds). The Industrial Revolution and British Society (1993), Cambridge University Press, Cambridge 254-282
131. von Tunzelmann G.N. Steam Power and British Industrialization to 1860 (1978), Clarendon Press, Oxford
132. Vos R. Drugs Looking for Diseases (1991), Kluwer Academic Publishers
133. Weatherall M. In Search of a Cure: A History of Pharmaceutical Discovery (1990), Oxford University Press, Oxford
134. Webster A., Martin P., Lewis G., and Smart A. Integrating pharmacogenetics into society: in search of a model. Nature Reviews Genetics 5 (2004) 7-13
135. Zeneca, 1996. Annual Report. London.